- Home
- BTOG vs CPHI Comparison
BTOG vs CPHI Comparison
Compare BTOG & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTOG | CPHI |
|---|---|---|
| Founded | 2018 | N/A |
| Country | Singapore | China |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 6.1M |
| IPO Year | 2018 | 2008 |
Fundamental Metrics
Financial Performance| Metric | BTOG | CPHI |
|---|---|---|
| Price | $2.72 | $0.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 96.9K | 77.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 70.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,528,929.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.08 | $0.12 |
| 52 Week High | $5.96 | $14.00 |
Technical Indicators
Market Signals| Indicator | BTOG | CPHI |
|---|---|---|
| Relative Strength Index (RSI) | 53.89 | 22.72 |
| Support Level | $2.59 | $0.60 |
| Resistance Level | $2.97 | $0.69 |
| Average True Range (ATR) | 0.39 | 0.12 |
| MACD | -0.15 | -0.00 |
| Stochastic Oscillator | 18.94 | 4.43 |
Price Performance
Historical ComparisonAbout BTOG Bit Origin Limited
Bit Origin Ltd is seeking opportunities in deploying new technologies, crypto asset mining and blockchain technologies in Singapore. The company has focused on building the Bitcoin mining ecosystem through incubations, strategic investments, and acquisitions. It derives all of its revenue from Bitcoin mining.
About CPHI China Pharma Holdings Inc.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.